Navigating 14 Analyst Ratings For Amgen
Portfolio Pulse from Benzinga Insights
Amgen (NASDAQ:AMGN) has received varied analyst ratings over the last quarter, ranging from bullish to bearish. Analysts have set a 12-month average price target of $349.36, reflecting a 4.55% increase from the previous target. Key analysts have maintained or raised their ratings, with price targets ranging from $215.00 to $405.00. Amgen's financial performance shows strong net margins and ROE, but a high debt-to-equity ratio indicates financial risk.
October 22, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen has received mixed analyst ratings, with a 12-month average price target of $349.36, indicating a 4.55% increase. Analysts have maintained or raised their ratings, with price targets ranging from $215.00 to $405.00. Amgen's financials show strong net margins and ROE, but a high debt-to-equity ratio poses financial risk.
The mixed analyst ratings with a slight upward trend in price targets suggest a positive short-term outlook for Amgen. The company's strong financial metrics, such as net margins and ROE, support this view. However, the high debt-to-equity ratio is a risk factor that investors should consider.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100